Optimising antipsychotic prescribing in schizophrenia : understanding the factors contributing to antipsychotic polypharmacy and personalising treatment to improve pharmacotherapy
(2023)
Files
Thèse_Lagreula_Juliette.pdf
Open Access - Adobe PDF
- 3.1 MB
Details
- Authors
- Supervisors
- Abstract
- Schizophrenia is one of the most severe psychiatric illnesses, and affects about 1% of the world's population. Antipsychotics are the only drugs currently registered for its treatment. Antipsychotic polypharmacy, the simultaneous use of two or more antipsychotics by a patient, is common worldwide for the treatment of schizophrenia, although its superior efficacy over antipsychotic monotherapy is not supported by high-quality evidence. Worse, patients on antipsychotic polypharmacy experience poorer outcomes than those on antipsychotic monotherapy. With the help of translational research and a multidisciplinary team, the aim of the present thesis is to provide insight about the ways of improving individual pharmacotherapy with antipsychotics in patients suffering from schizophrenia. This project paves the way for future implementation studies aimed at deprescribing antipsychotics to reach antipsychotic monotherapy.
- Affiliations
Citations
Lagreula, J. (2023). Optimising antipsychotic prescribing in schizophrenia : understanding the factors contributing to antipsychotic polypharmacy and personalising treatment to improve pharmacotherapy. https://hdl.handle.net/2078.5/234173